Luca Maccioni

发表

Deficient IL‐6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis

R. Bataller, C. Hellerbrand, N. Lanthier, 2019, Hepatology communications.

Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder

O. Quehenberger, Aaron M. Armando, Xinlian Zhang, 2022, Metabolites.

Liver alterations are not improved by inulin supplementation in alcohol use disorder patients during alcohol withdrawal: A pilot randomized, double-blind, placebo-controlled study

A. Neyrinck, N. Delzenne, P. de Timary, 2022, EBioMedicine.

Duodenal CD8+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol‐associated liver disease in humans

N. Lanthier, I. Leclercq, G. Bommer, 2022, Alimentary pharmacology & therapeutics.

Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans

D. Fouts, I. Leclercq, P. de Timary, 2020, Gut microbes.

Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease

I. Leclercq, B. Schnabl, P. Stärkel, 2021, International journal of molecular sciences.

Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans

G. Laloux, I. Leclercq, S. Leclercq, 2023, Hepatology communications.

Alcohol-associated bowel disease: new insights into pathogenesis

I. Leclercq, Y. Horsmans, G. Kunos, 2023, eGastroenterology.

Alcohol-associated liver disease

B. Mackowiak, Luca Maccioni, Yaojie Fu, 2024, The Journal of clinical investigation.